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Abstract
Background: Heparin-binding hemagglutinin (HBHA) protein is a surface adhesin that mediates the attachment of Mycobacterium
tuberculosis to host cells by its own unique, carboxyl-terminal region. The methylated HBHA has a specific motif with a lysine-,
alanine-, and proline-rich domain. More recently, it has been shown that HBHA protein has potential activity in stimulating im-
mune responses, and is a promising new candidate for diagnostic applications besides a protective antigen against tuberculosis.
Objectives: The aim of this study was to isolate a mycobacterial latency gene (hbha), and subsequently produce its protein as a new
antigen for the Interferon-Gamma Release Assay test (IGRAs).
Methods: In the present work, hbha and mtb32C genes were isolated from the Mycobacterium tuberculosis H37Rv genome using the
polymerase chain reaction (PCR) method. The PCR products and pet21+ vector were digested with specific restriction enzymes and
then submitted to the ligation procedure. Escherichia coli BL21-CodonPlus (DE3) competent cells were transformed with the recom-
binant mtb32C-hbha -pet21+ vector. Expression of recombinant protein (Mtb32C-HBHA) was confirmed with Sodium Dodecyl Sulfate
Polyacrylamide Gel Electrophoresis (SDS-PAGE) and western blot methods.
Results: Detection of a 500-bp gene and sequencing of recombinant pet-mtb32C-hbha vector, all confirmed the accuracy of the
cloning procedure. A 36-KDa band of Mtb32C-HBHA protein was also detected by western blotting.
Conclusions: In this study, expression of Mtb32C-HBHA protein was successfully done, in the prokaryotic system. Further studies
are needed to evaluate the efficacy of recombinant Mtb32C-HBHA protein in diagnosis of latent tuberculosis.
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1. Background
Mycobacterium tuberculosis, the causative agent of tu-
berculosis, is a strike aerobic, intracellular pathogen,
which in most cases enter the body via the respiratory
tract. In 2012, the world health organization (WHO) re-
ported 8.6 million cases of tuberculosis worldwide with
most occurrences reported in Asia (58%) and Africa (27%).
From the site of initial infection, the lungs, the tubercle
bacilli spread to other parts of the body through the lym-
phatic or blood vessels. Tuberculosis remains a significant
difficulty for human health in most parts of the world, with
about two million deaths, annually (1, 2). Epidemiolog-
ically, 30% of infected individuals do not have any signs
of tuberculosis disease and are unable to spread infection
to others. This condition is known as latent tuberculosis
infection, for the diagnosis of which there are currently
two main tests, including tuberculin skin test (TST) and
interferon-gamma release assays (IGRAs).
Tuberculin skin test has a diagnostic challenge in diag-
nosis of tuberculosis because it has a low specificity and
there is cross-reactivity with environmental mycobacteria
and Bacille Calmette-Guerin (BCG) vaccine in vaccinates (3,
4). Over the past decade, many studies have resulted in
the design and development of a new diagnostic method,
known as Interferon-gamma release assays (IGRAs). These
assays are based on the principle that the T-cells of individ-
uals, who have been infected with M. tuberculosis, secrete
interferon gamma (IFN)-γ in response to specific antigens
of M. tuberculosis. Furthermore, IGRAs were developed to
replace conventional tuberculin skin test for the diagno-
sis of latent tuberculosis infection because IGRAs have high
specificity and several advantages over TST (4).
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Heparin-binding hemagglutinin (HBHA) protein is a
mycobacterial adhesin and virulence factor that is re-
quired for dissemination of M. tuberculosis from the lung
to internal organs, such as the spleen. Absence of the
hbha gene in mutant strains leads to deficiency in extra-
pulmonary dissemination (5-7). The hbha gene present in
M. tuberculosis and BCG genome is responsible for binding
of bacteria to alveolar epithelial cells (8-10). Its C-terminal
domain bears post translational modification; methyla-
tion of repeated lysine-rich motifs. Previous studies indi-
cated that HBHA is an immunogenic antigen and plays a
significant role in inducing humoral and cellular immune
responses (11-14). HBHA protein could induce high levels of
anti-HBHA antibodies and interferon gamma (IFN)-γ from
T-lymphocytes in most patients infected with M. tuberculo-
sis compared to BCG-immunized individuals. These stud-
ies suggest that HBHA protein is an appropriate antigen
for tuberculosis diagnostic tests, such as IGRAs. In fact,
the cornerstone of the immune response to mycobacte-
rial infection is the production of gamma-interferon (IFN)-
γ by CD4 cells. Interferon-gamma release assays (IGRAs)
are new techniques for diagnosis of latent tuberculosis in-
fection, and HBHA antigen is used as a new candidate for
IGRAs (15-17).
2. Objectives
In the present study, hbha gene along with mtb32C
genes were isolated from M. tuberculosis H37Rv strain and
cloned in the pet21+ vector for enhancing expression and
raising antigenicity of the hbha gene. The expression of
recombinant plasmid was verified in Escherichia coli BL21
(DE3) CodonPlus strain.
3. Methods
3.1. Isolation of mtb32C and hbha Genes from the Mycobac-
terium tuberculosis Genome
The entire DNA of M. tuberculosis was prepared as
described, previously (18). By using specific primers de-
signed with DNAMAN (Lynnon Biosoft version 5.2) and
Gene Runner (Version 3.05, Hastings Software Inc.) soft-
ware, the mtb32C and hbha genes were isolated from the M.
tuberculosis H37Rv genome. Two sets of primers were used
as follows: 5’-ATATCATATGACGGCCGCGTCCGATAACT-
3’ as the forward primer and 5’-
ATATGAATTCAGCAGGGGGTCCCTCGGCCAATGT-
3’ as the reverse primer for mtb32C and 5’-
ATATGAATTCATGGCTGAAAACTCGAACATT-’3 as the forward
primer and 5’- ATATGGATCCCTAatgatgatgatgCTTCTGGGT-
GACCTTCTT -3’ as the reverse primer for the hbha gene.
Underlined letters indicate NdeI, EcoRI, and BamHI re-
striction sites, respectively. Small and bold letters in the
reverse primer of hbha gene represent 4 Histidine (His)-
tag and stop codon sequences. Polymerase Chain Reaction
(PCR) was used for genes amplification. The mixture con-
taining 1 µg of the DNA sample, 2.5 mM MgCl2 (Fermentas,
Germany), 0.5 mM of each dNTPs (Fermentas, Germany),
10 pmol of each primer (CinnaGen, Iran), and 1 unit of Taq
polymerase (CinnaGen, Iran) was prepared and then trans-
ferred to a thermocycler (Applied Biosystem,USA). Thermo-
cycling conditions for amplification of both mtb32C and
hbha genes was 35 cycles (95°C for 1 minute, 58°C for 1
minute, and 72°C for 1 minute) after an initial denaturation
step of at 95°C for 5 minutes. Finally, amplified DNA frag-
ments were assessed by agarose gel electrophoresis and
stained with the Green Viewer (Pars Tous, Iran).
3.2. Construction of Recombinant mtb32C -hbha -pet21 + Vector
First, the hbha gene and pet 21+ were digested with
BamHI and EcoRI restriction enzymes and then ligated to-
gether as described in a previous paper (18). Pet21 + vector
containing the hbha gene and PCR product of the mtb32C
gene were digested with NdeI and EcoRI and subsequently
fused together using the T4 DNA ligase enzyme. All diges-
tion and ligation procedures were described in detail, pre-
viously (19).
3.3. Real Time-Polymerase Chain Reaction Assay
To confirm the presence of mtb32C - hbha mRNA in
transformed E. coli BL21 (DE3) CodonPlus cells with recom-
binant vector, the RT-PCR method was employed. All pro-
cedures were performed according to the manufacturer’s
instructions and previous studies (18-20).
3.4. SodiumDodecyl SulfatePolyacrylamideGel Electrophoresis
andWestern Blot Analysis
To study the expression and production of Mtb32C-
HBHA recombinant protein, SDS-PAGE and Western
blot methods were employed. Transformed E. coli BL21
(DE3) CodonPlus cells with recombinant vector were
cultured in Luria-Bertani (LB) broth medium at 37°C for
16 hours. After the incubation period, Isopropyl β-D-
1-Thiogalactopyranoside (IPTG) (Sigma, USA) at a final
concentration of 1 mM was added and after 2 hours, 1 mL
of cell culture was centrifuged and mixed with 2x loading
buffer (100 mM Tris-Cl, pH = 6.8; 4% (w/v) Sodium Dodecyl
Sulfate (SDS); electrophoresis grade, 0.2% (w/v) bromophe-
nol blue, 20% (v/v), and glycerol, 200 mM dithiothreitol
(DTT). The mixture was boiled for 5 minutes at 100 ºC.
The prepared sample was electrophoresed on 12% Sodium
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Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE). The presence of recombinant Mtb32C-HBHA protein
was confirmed using specific antibodies in Western blot
analysis (19, 20).
4. Results
The recombinant vector containing mtb32C and hbha
genes fromM. tuberculosisH37Rv was constructed. This vec-
tor was (mtb32C-hbha-pet21+) sequenced with the T7 pro-
moter and T7 terminator primers that showed 100% iden-
tity with related sequences in Genbank. Colony -PCR and
sequencing methods confirmed correction of all cloning
procedures (Figure 1). The production of related mRNA and
chimeric protein of about 35.5 kDa was confirmed with the
RT-PCR method and Western blot analysis using anti-His
Tag antibody, respectively (Figures 2 and 3).
Figure 1. Colony-PCR Results That Show Amplification of About 1000 bp of mtb32C-
hbha Fragment Using mtb32C-hbha Specific Primers (lane 2, 3); Lane M: 100 bp DNA
Size Marker (Fermentas, Germany)
5. Discussion
Despite available vaccines, drugs, and diagnostic meth-
ods, tuberculosis infection remains as a concern in the 21st
Figure 2. Detection of mtb32C-hbha mRNA in Transformed and Non-Transformed
Escherichia coli BL21 (DE3) CodonPlus Cells by Real Time-Polymerase Chain Reaction
Analysis
Using specific primers designated formtb32C-hbhagenes showed negative results in
non-transformed cells (lane 2) and a band with a size of 1000 bp in transformed cells
with recombinant vector (lane 3). Lane 1: 1 kb DNA size marker
century and is still the leading cause of death more than
any other single infectious disease. The lungs are the ini-
tial route of infection and M. tuberculosis could enter and
replicate within the resident alveolar macrophage, den-
dritic cells, and epithelial cells (pneumocytes), using sev-
eral receptors. It has been estimated that two billion peo-
ple worldwide have latent infection and are at risk of active
tuberculosis (21-23).
Latent tuberculosis is defined as a condition, in which
M. tuberculosis remains inside an infected macrophage in
dormant state without any clinical manifestations. It has
been estimated that one-third of the world’s population
has LTBI. About 5% to 10% of individuals, who have latent
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Figure 3. Western Blot Analysis That Confirms the Presence of RecombinantMtb32C-
HBHA Protein (36 kDa Protein Band) in Transformed Bacteria (Lane 1); (Lane 2): Neg-
ative Control; M: Protein Size Marker (Fermentas, Germany)
tuberculosis will experience reactivation of active tubercu-
losis with defined clinical symptoms in their lifetime while
this rate will be higher in immunocompromised patients.
In fact, subjects with latent infection serve, as a source of
tuberculosis infection and a serious threat for healthy peo-
ple and the community. Any changes in the immune sys-
tem after exposure to specific conditions, such as malnutri-
tion, acute infections, or other suppressive immunity con-
ditions increase the risk of active tuberculosis (24-26).
The identification and treatment of LTBI is a principle
part of tuberculosis control strategies and decreases the in-
cidence of disease reactivation. The risk of progression of
LTBI to active disease is very high within patients with im-
munocompromised conditions, chronic renal failure dis-
ease or patients receiving chemotherapy (25). Treatment of
latent tuberculosis with isoniazid reduces risk of progres-
sion of disease towards active and contagious forms by 75%
to 90%. Nowadays, tuberculin skin test (TST) is the most
widely used diagnostic test for LTBI that was first described
by Koch in 1890 and developed by Mantoux in 1907. The
TST is based on delayed hypersensitivity responses (DTH) of
memory T cells to purified protein derivative (PPD) fromM.
bovis.
Tuberculin skin test is a simple and cost effective, and
the world health organization (WHO) has approved the
test for the recognition of prior exposure to M. tubercu-
losis. Sensitivity of the test in patients with positive cul-
ture for M. tuberculosis ranges between 70% and 90%, how-
ever, this test has low specificity with several disadvan-
tages, including false-negative results, which may be com-
mon in immunosuppressed individuals, and very young or
very old cases. False-positive results could be due to BCG-
vaccinated people and in those, who are in contact with
non-tuberculous mycobacteria. Other limitations are as
follows, a need for a patient visit after PPD administration,
inter-observer variability and disability in differentiating
recent from latent infection. As a result, TST is not consid-
ered as a gold standard test (27, 28).
The low specificity of TST is related to the PPD used for
TST that encompasses abundant antigens that are nearly
the same as in BCG or non-tuberculous mycobacterium
antigens, therefore more accurate tests, for detecting ac-
tive tuberculosis is urgently needed (29). The current anti-
gen is introduced for IGRAs to detect LTBI. The IGRA (IFN-
γ) is a novel test based on the measurement of IFN-γ re-
lease from sensitized T cells in response to mycobacterial-
specific antigens, which is used for tuberculosis diagnosis.
Nowadays, ESAT-6, CFP-10, and tuberculosis 7.7 antigens are
used in IGRA because they are extremely specific to M. tu-
berculosis. In these tests, the amount of interferon-gamma
released from sensitized T lymphocytes are measured by T-
SPOT.
Tuberculosis and quantity FERON-tuberculosis are 2
commercially gold standard diagnostic tests for diagno-
sis of tuberculosis infection (29-31). Using IGRA tests, peo-
ple, who were infected with tuberculosis could be distin-
guished from vaccinated or individuals infected with non-
tuberculosis mycobacteriu M. tuberculosis tests are more
specific than TST because they are able to detect tubercu-
losis infection from BCG vaccinated individuals yet they
cannot discriminate old infections from recent infections.
More recently, several studies reported the use of HBHA
protein as HBHA-IGRA test for detection of latent tubercu-
losis disease. Heparin-binding hemagglutinin protein par-
ticipates in extra pulmonary tuberculosis that may involve
other organ of the body (29, 32).
In one study, Dessein et al. reported that native HBHA
protein, purified from BCG, was used in IGRA test for de-
tection LTBI in dialysis patients (33). This study showed
that naive HBHA-IGRA compared to QFT is much more sen-
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sitive for the detection of LTBI. Hougardy et al. demon-
strated that HBHA protein-based IGRA test could more effi-
ciently detect latent infection (> 2 years) than tuberculosis
gold in-tube (QFT-IT) test (31). In all previous studies, native
HBHA protein was used and none of them evaluated the re-
combinant form (34).
6. Conclusions
Considering that HBHA protein has an important role
in infectivity, pathogenesis, and detection of M. tuberculo-
sis and the native HBHA protein elicits different immune
responses compared to the recombinant form, this study
produced a fusion protein (Mtb32C-HBHA) in the prokary-
otic system. Many more studies would be required for
identification of Mtb32C-HBHA utility for the detection of
M. tuberculosis infection in latent patients.
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